Articles Tagged With:
-
Patient access ‘begs for lean principles’
"Lean” methodology is used for any quality improvement effort in registration areas at Kaleida Health in Buffalo, NY.
-
Early Recognition and Management of ARDS
ABSTRACT & COMMENTARY: Early recognition of ARDS with strict adherence to low tidal volume ventilation is important for reducing mortality in the ICU.
-
The High and Low Cost of Dying
Nurses perceive increased quality of dying with lower costing end-of-life care, while underinsured families perceive increased quality of dying with higher costs.
-
Sleep-promoting Interventions for Critically Ill Patients
ABSTRACT & COMMENTARY: Efforts have been made over the past couple of years to test and implement interventions in the ICU to promote sleep.
-
More About Pistachios: Benefits in Cardiometabolic Syndrome
SYNOPSIS: Improvements in some, but not all, lipid parameters were seen by substituting some carbohydrates with two servings of pistachios daily in people with elevated serum LDL cholesterol.
-
The Benefits of a Diet Rich in Omega 3s
Your patients' benefits and risks of eating fish rich in omega-3 fatty acids.
-
Pistachios and Metabolic Risk Factors
This study is a randomized, crossover clinical trial demonstrating that a pistachio-rich diet significantly reduced fasting glucose, insulin, and insulin resistance compared to the control diet group in prediabetic individuals.
-
Clinical Briefs
Topics: Metformin: Have we Been Overcautious in CKD?, Reduction in Prostate, and Doing the Right Thing for Acute Bronchitis in Healthy Adults: Antibiotics
-
Edoxaban Tablets (Savaysa™)
The third oral factor Xa inhibitor has been approved by the FDA. Edoxaban is the fourth target-specific oral anticoagulant (TSOA) to enter the market following dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis). Edoxaban is manufactured by Tokyo-based Daiichi Sankyo Company and marketed by Daiichi Sankyo as Savaysa.
-
The Economic Burden of Undiagnosed Pre-diabetes
The economic burden of diagnosed and undiagnosed diabetes, gestational diabetes, and prediabetes has exceeded $322 billion.